



July 28, 2023

Company name: TMS Co., Ltd.
Name of representative: Takuro Wakabayashi, Chief Executive Officer
(Securities code: 4891; Growth Market)
Inquiries: Go Ito, Chief Financial Officer
(Telephone: +81-42-307-7480)

Notice regarding the development of TMS-007 (BIIB131)

TMS Co., Ltd. (the “Company”) hereby announces that the Estimated Study Start Date of a Phase 2b clinical trial for TMS-007/BIIB131 on ClinicalTrials.gov* (<https://clinicaltrials.gov/>) was updated on July 27, 2023, by Biogen, Inc. (“Biogen”). To date, Biogen’s intention on the update of Estimated Study Start Date, nor the result of its reassessment have not been made public.

Biogen did not make any specific announcement regarding the development of TMS-007/BIIB131 at its Second Quarter 2023 earnings call held on July 25, 2023. However, Biogen continues listing of TMS-007/BIIB131 on the pipeline table in the presentation material used in the earnings call.

Underlined information has been updated.

Phase:	Phase IIb
Sponsor:	Biogen
Estimated Enrollment:	760 participants
Estimated Study Start Date:	After update: <u>December 1, 2023</u> Before update: <u>August 21, 2023</u>
Estimated Study Completion Date:	July 7, 2025
NCT Number:	NCT05764122
URL	https://clinicaltrials.gov/ct2/show/NCT05764122

*Clinicaltrials.gov

ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions. The Website is maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH).

End